Brokerage firm Citigroup Maintains its rating on PAREXEL International Corporation(NASDAQ:PRXL). In a research note issued to the investors, the brokerage major Raises the price-target to $80.00 per share. The shares have been rated Buy. The rating by Citigroup was issued on Aug 5, 2016.
In a different note, On Jul 18, 2016, William Blair said it Downgrades its rating on PAREXEL International Corporation. The shares have been rated ‘Market Perform’ by the firm. Credit Suisse said it Initiates Coverage on PAREXEL International Corporation, according to a research note issued on Jun 21, 2016. The shares have been rated ‘Outperform’ by the firm.
PAREXEL International Corporation (PRXL) shares turned negative on Wednesdays trading session with the shares closing down -0.37 points or -0.53% at a volume of 2,09,589. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $69.9899. The peak price level was also seen at $69.9899 while the days lowest was $69.12. Finally the shares closed at $69.37. The 52-week high of the shares is $76.17 while the 52-week low is $56. According to the latest information available, the market cap of the company is $3,669 M.
PAREXEL International Corporation(PRXL) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q4.Company reported revenue of $538.60M. Analysts had an estimated revenue of $532.58M. Earnings per share were $0.94. Analysts had estimated an EPS of $0.93.
Several Insider Transactions has been reported to the SEC. On Jun 14, 2016, A Dana Jr Callow (director) sold 3,000 shares at $60.04 per share price.Also, On Jun 3, 2016, Eduard E. Holdener (director) sold 700 shares at $62.98 per share price.On May 26, 2016, Ulf I Schneider (SVP & Chief Admin. Officer) sold 7,500 shares at $62.00 per share price, according to the Form-4 filing with the securities and exchange commission.
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.